Curium agreed to acquire Lantheus in a deal valued up to $8 billion, combining Curium’s theranostics manufacturing platform with Lantheus’ U.S. radiodiagnostics business. Under the terms, Curium will pay $102.50 per Lantheus share in cash at closing, with additional contingent value rights that could raise total consideration to about $114.50 per share. The combined company is expected to operate across the nuclear medicine supply chain, from isotope production through targeted radionuclide therapy and diagnostics. Lantheus’ portfolio includes prostate cancer imaging agent Pylarify, cardiac ultrasound enhancing agent Definity, and beta-amyloid PET imaging agent Neuraceq. The transaction is expected to close in the first half of 2027, pending Lantheus shareholder and regulatory approvals, and would leave Lantheus privately held.